Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854733 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL5854738 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL7119152 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL5853223 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL1017052 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL5853219 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL6696775 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LPAR2LPAR3LPAR1CNR1 | |
| SCHEMBL8003221 | 0.97 | — | — | |
| SCHEMBL1017304 | 0.97 | — | — | |
| SCHEMBL765792 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| EP-2487149-A1 | METHOD FOR PRODUCING KETONE | JX Nippon Oil & Energy Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120197036-A1 | METHOD FOR MANUFACTURING KETONE | OSAKA UNIVERSITY (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2009117594-A1 | FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | ALDH1A1 815/4885LPAR2 2403/4885LPAR3 3236/4885 |
| US-20120197036-A1 | METHOD FOR MANUFACTURING KETONE | CBR1, CBR3, DUOX1 | ALDH1A1 79/4885LPAR2 3613/4885LPAR3 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.